What's New: Browse by Mechanism
A third way to explore the trial field — by how a drug works — plus twelve new drug pages, patient-focused ASCO 2026 coverage, and more accurate matching.
Browse by Mechanism: 10 Drug-Class Hubs
Patients increasingly ask about trials not by cancer type or by a single brand-name drug, but by how the treatment works — "what antibody-drug conjugate trials are open?", "what's happening with the KRAS inhibitors?", "which bispecifics are being tested for my myeloma?" A single drug page couldn't answer those, because a mechanism spans many drugs, many sponsors, and many cancers at once.
So June added a new browse axis: the mechanism hub. Each hub gathers every active trial for a whole drug class — across cancers — and explains, in plain language, how that class works and which agents lead it. Ten launched in June:
- HER2 ADCs — antibody-drug conjugates targeting HER2, anchored by T-DXd (Enhertu)
- TROP2 ADCs — the TROP2 antibody-drug conjugate class (Trodelvy, Datroway, and the next wave)
- KRAS Inhibitors — G12C anchors (sotorasib, adagrasib) plus the pan-RAS and G12D next generation
- CDK4/6 Inhibitors — the HR+/HER2− breast-cancer backbone (palbociclib, ribociclib, abemaciclib)
- PARP Inhibitors — BRCA/HRD-targeted therapy across ovarian, breast, prostate, and pancreatic cancers
- PSMA Radioligand Therapy — targeted radiation for prostate cancer (Pluvicto and the alpha-emitter wave)
- CLDN18.2 Targeted Therapies — the Claudin 18.2 class (zolbetuximab, CLDN18.2 ADCs, CAR-T)
- Bispecific Checkpoint Inhibitors — dual-target immunotherapy (PD-1/CTLA-4, PD-1/VEGF, PD-1/TIGIT)
- BCMA Bispecifics — BCMA×CD3 T-cell engagers for multiple myeloma
- GPRC5D Bispecifics — the GPRC5D×CD3 myeloma class, for patients sequencing after BCMA
Every hub re-aggregates from the trial corpus, so the trial lists and counts stay current without manual upkeep — the same approach as the disease landscape pages. Browse the full set at /mechanisms. (An 11th hub, multikinase inhibitors, has since followed in early July, with more on the way.)
Twelve New Drug Pages
If you've heard about a specific drug and want to know which trials are actively recruiting for it, the drug catalog more than doubled in June — twelve new pages, each showing the drug's mechanism, its active trials grouped by cancer, and the Phase 3 acronyms you can search to read further:
- Lynparza (olaparib) and Zejula (niraparib) — PARP inhibitors for BRCA/HRD-driven cancers
- Ibrance (palbociclib) — CDK4/6 inhibitor for HR+/HER2− breast cancer
- Trodelvy (sacituzumab govitecan) and Datroway (datopotamab deruxtecan) — TROP2 antibody-drug conjugates
- Krazati (adagrasib) — KRAS G12C inhibitor for NSCLC and colorectal cancer
- Pluvicto (177Lu-PSMA-617) — PSMA-targeted radioligand therapy for prostate cancer
- Lenvima (lenvatinib) — multikinase inhibitor used across liver, kidney, thyroid, and endometrial cancers
- Tebentafusp (Kimmtrak) — T-cell engager for HLA-A*02:01–positive uveal melanoma
- Talquetamab (Talvey) and Teclistamab (Tecvayli) — GPRC5D and BCMA bispecifics for multiple myeloma
- Intismeran autogene (V940 / mRNA-4157) — a personalized neoantigen mRNA cancer vaccine in adjuvant trials
The drug pages also got more interactive this month: clicking "Find Matching Trials" on any drug page now opens the wizard with a quick cancer-type chooser, so you land on the questionnaire ready to search. And the ivonescimab and cadonilimab pages gained expandable per-trial detail, so you can drill into any listed study without leaving the page.
Browse them all at /drugs.
ASCO 2026, Written for Patients
ASCO — the largest annual oncology meeting — took place in early June. Most conference coverage is written for oncologists; we wrote ours for patients with the disease. New this month:
- ASCO 2026 Wrap-Up: Seven Patient Takeaways — what actually changed for patients, without the jargon
- Pre-ASCO 2026: Non-Small-Cell Lung Cancer — joining our ADC, T-cell-engager, pancreatic, and prostate previews
We also went back through the earlier ASCO preview posts and the related drug pages after the data was presented, adding "now concluded" framing and refreshing the affected drug pages with what was actually reported — so the previews don't read as stale once the meeting is over.
More Accurate Matching, Under the Hood
Several June changes aren't visible as new pages but make the trial matching itself more accurate:
- An eligibility-parsing bug fix. A trial criterion phrased as "not included" was in some cases being read as a criterion you met — a text-matching slip where the word "included" inside "not included" flipped the result. It's fixed, so exclusion criteria are read correctly.
- Better ordering for pretreated patients. When your profile signals a specific biomarker or a heavily-pretreated history, matching trials now surface higher in the list rather than getting buried.
- Fewer dead-end results. Trials that are marked "not yet recruiting" with no open sites in your country are now filtered out when you've set a location, and there's a display-side safety net so a search never lands you on an empty page.
- Stage-mismatch handling. Trials requiring a clearly different disease stage than yours are now deprioritized deterministically, so the top of your list stays relevant.
The Wizard Got Much Faster
The wizard's first step — turning your cancer type into a working search — used to take around 20 seconds for common cancers while the questionnaire was prepared behind the scenes. It's now effectively instant: for the cancers most people search, that wait went from roughly 20 seconds to a fraction of a second. Less common searches that can't be prepared ahead of time are also noticeably faster than before.
Two changes did most of the work: the data for common cancers is now prepared in advance rather than on demand, and a slow save step that used to hold up your request was moved into the background.
The wizard also no longer breaks on unfamiliar input. If you enter a disease name the system doesn't immediately recognize — a rare subtype, a translation, or a typo — it used to occasionally error out and lose your place. It now falls back gracefully and still returns a usable search.
Smaller Improvements
- Mobile polish. A pass over the results and trial-detail pages fixed layout issues on phones.
- Neuroendocrine tumor grading. The questionnaire now accepts a Ki-67 percentage directly for neuroendocrine tumors, instead of asking you to translate it into a grade.
- Easier to find in search. Structured breadcrumb data was added across the site so pages show a clearer trail in Google results.
- Fresher disease pages. Over two dozen disease pages were re-verified against the trial corpus and updated with post-ASCO 2026 data, so their trial counts and Phase 3 lists reflect the current field.
Try It
Questions or feedback? Contact us